Research and Markets: Perennial Allergic Rhinitis Pipeline Review, H2 2015
September 04 2015 - 8:25AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/b753zj/perennial) has
announced the addition of the "Perennial Allergic Rhinitis -
Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the
therapeutic development for Perennial Allergic Rhinitis, complete
with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players
involved in the therapeutic development for Perennial Allergic
Rhinitis and special features on late-stage and discontinued
projects.
The report enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and
MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Adamis Pharmaceuticals Corporation
- FAES Farma SA
- GenMont Biotech Inc.
- GlaxoSmithKline Plc
- Hanmi Pharmaceuticals, Co. Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Shionogi & Co., Ltd.
- VentiRx Pharmaceuticals, Inc.
For more information visit
http://www.researchandmarkets.com/research/b753zj/perennial
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150904005289/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Respiratory